Skip to main content
Press release October 22, 2026

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Acumen Pharmaceuticals, Inc. (ABOS)

We couldn't retrieve the full text for this release. Read it on the company's site.

Read full release on company site